Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 3/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8930160 | 1.00 | PARP15 (0.55) | PARP15PARP10PARP2TDP1KDM1A | |
| Ammonia Solution, Strong SCHEMBL28413630 | 0.98 | PARP15 (0.53) | PARP15PARP10PARP2TDP1KDM1A | |
| SCHEMBL14451132 | 0.92 | HPGD (0.52) | PARP15PARP10PARP2TDP1KDM1A | |
| SCHEMBL11164865 | 0.92 | PARP15 (0.57) | PARP15PARP10PARP2TDP1KDM1A | |
| SCHEMBL18374444 | 0.92 | PARP15 (0.57) | PARP15PARP10PARP2TDP1KDM1A | |
| SCHEMBL17296955 | 0.91 | PARP15 (0.47) | PARP15PARP10PARP2TDP1KDM1A | |
| SCHEMBL16141973 | 0.91 | PARP15 (0.51) | PARP15PARP10PARP2TDP1KDM1A | |
| SCHEMBL81903 | 0.90 | PARP15 (0.58) | PARP15PARP10PARP2TDP1KDM1A | |
| SCHEMBL29024848 | 0.89 | PARP15 (0.64) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL14570008 | 0.88 | KDM1A (0.49) | PARP15PARP10PARP2TDP1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11173145-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210300908-A1 | S1P1 AGONIST AND APPLICATION THEREOF | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2021-09-30 | — | — | US | disclosed |
| EP-3865475-A1 | PROCESS FOR PREPARING PYRIDONE AMIDES WHICH ARE MODULATORS OF SODIUM CHANNELS AND INTERMEDIATE COMPOUNDS USED THEREIN | Vertex Pharmaceuticals Incorporated (US) | 2021-08-18 | — | — | EP | disclosed |
| WO-2021156636-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | KING'S COLLEGE LONDON (GB) | 2021-08-12 | — | — | WO | disclosed |
| EP-3819303-A1 | GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE | Shanghai Hutchison Pharmaceuticals Limited (CN) | 2021-05-12 | — | — | EP | disclosed |
| US-10981900-B2 | Spiro compound and use thereof | MEDSHINE DISCOVERY INC. (CN) | 2021-04-20 | — | — | US | disclosed |
| EP-3239134-B1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200048235-A1 | SPIRO COMPOUND AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-02-13 | — | — | US | disclosed |
| WO-2018098207-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20100166655-A1 | 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100166655-A1 | 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-07-01 | — | — | US | disclosed |
| WO-2009158473-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2007104783-A2 | 1,4 -DI SUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPT0R MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-1801619-A2 | Substrate, method for producing the same, and patterning process using the same | Shin-Etsu Chemical Co., Ltd. (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-20070037894-A1 | Multifunctional menomers and polyarylene compsotions therefrom | HAHNFELD JERRY L | 2007-02-15 | — | — | US | disclosed |
| US-20070037894-A1 | Multifunctional menomers and polyarylene compsotions therefrom | HAHNFELD JERRY L | 2007-02-15 | — | — | US | disclosed |
| WO-2003048109-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048235-A1 | SPIRO COMPOUND AND USE THEREOF | S1PR1, S1PR2, S1PR3 | PARP15 2168/4885PARP10 2050/4885PARP2 2337/4885 |
| US-20100166655-A1 | 1, 4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | PARP15 3048/4885PARP10 2746/4885PARP2 3199/4885 |
| US-11173145-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | TPH2, TPH1, IDO2 | PARP15 1781/4885PARP10 2376/4885PARP2 2187/4885 |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | PARP15 1899/4885PARP10 1526/4885PARP2 4098/4885 |
| US-10981900-B2 | Spiro compound and use thereof | S1PR1, S1PR2, S1PR3 | PARP15 2168/4885PARP10 2050/4885PARP2 2337/4885 |
| US-20210300908-A1 | S1P1 AGONIST AND APPLICATION THEREOF | S1PR1, S1PR2, S1PR3 | PARP15 1755/4885PARP10 1867/4885PARP2 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.